List view / Grid view


Protagen AG appoints Bernhard Kirschbaum as new Board Member

8 January 2015 | By PROTAGEN AG

PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board...

SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders

8 January 2015 | By SciFluor Life Sciences

SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...

Kymab and the Wellcome Trust initiate Ebola Project

16 December 2014 | By Kymab

Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...

New targeted drugs could treat drug-resistant skin cancer

15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute

A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...